查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
T 细胞疗法市场规模、份额和趋势分析报告，按方式、按疗法（CAR T 细胞、肿瘤浸润淋巴细胞）、按适应症（血液恶性肿瘤（淋巴瘤））、按分部预测，2023-2030 年
市场调查报告书
商品编码
1233261

T 细胞疗法市场规模、份额和趋势分析报告，按方式、按疗法（CAR T 细胞、肿瘤浸润淋巴细胞）、按适应症（血液恶性肿瘤（淋巴瘤））、按分部预测，2023-2030 年

T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 200 Pages | 商品交期: 2-10个工作天内

价格

T 细胞疗法市场增长和趋势

Grand View Research, Inc. 的最新报告显示，到 2030 年，全球 T 细胞疗法市场规模将达到 308.3 亿美元，2023 年至 2030 年的 CAGR 将达到 17.6%，预计将创历史新高

Kymriah 和 Yescarta 的主要批准推动了市场进程。 此类疗法的推出增强了该领域创新的现金流，从而促进了市场增长。

从一线干细胞移植和化疗到嵌合抗原受体 (CAR) T 细胞疗法的患者偏好不断变化，预计这将提供市场增长机会。 与此同时，正在测试 T 细胞疗法的疾病清单也在不断增加。 随着对其他领域的投资不断增加，肿瘤疾病备受关注。

多发性骨髓瘤患病率上升、白血病和淋巴瘤患病率上升导致 CAR-T 细胞疗法得到广泛采用，并正在推动市场增长。 根据白血病和淋巴瘤协会 (LLS) 的数据，美国估计约有 54,000 名 20 岁及以上的儿童和青少年患有淋巴瘤、白血病、骨髓瘤和骨髓增生异常综合征 (MDS)。 文件称，2021年美国将新增确诊癌症患者约1898160人，其中白血病、淋巴瘤和骨髓瘤的新增发病率为9.8%。

随着新疗法的推出，临床试验活动的增加预计将推动未来几年的市场增长。 例如，2021 年 12 月，诺华宣布推出其下一代 CAR-T 平台 T-ChargeTM，该平台将作为公司管道中许多新的研究性 CAR-T 细胞疗法的基础。 YTB323（抗 CD19）和 PHE885（抗 BCMA）是第一个在此平台上设计的诺华 CAR-T 细胞治疗药物，诺华将在 2021 年第 63 届美国血液学会年会暨博览会（ASH）上展示它已完成.

针对非血液系统恶性肿瘤的 CAR T 疗法的开发受到抗原问题和相关毒性问题的严重阻碍。 为了克服这一困难并提高 T 细胞疗法在脑肿瘤和黑色素瘤等适应症中的利用率，各大公司正在利用数据驱动的方法来研究这一领域。

T 细胞疗法市场报告要点

  • 从形式上看，由于临床试验中有大量 T 细胞疗法产品，基于研究的 T 细胞疗法市场预计将占据很大份额。
  • 由于监管机构批准的产品数量不断增加，预计未来几年商业化 T 细胞疗法将显示出巨大的市场份额。
  • 按产品类型划分，由于 CAR-T 疗法产品的临床试验增加，CAR-T 细胞疗法在 2022 年占据了该细分市场的主导地位。 此外，越来越多地使用这些疗法治疗各种癌症有望推动该领域的增长。
  • 血液系统恶性肿瘤在 2022 年占据了适应症部分的主导地位。 为了治疗淋巴瘤和急性淋巴细胞白血病 (ALL)，CAR T 细胞疗法最常见的靶标是 B 细胞上的 CD19，这导致五种 CAR T 疗法获得批准。
  • 北美在全球市场中占有压倒性的份额。 该地区的增长归因于临床试验的增加、强有力的研究和监管批准的增加，这些疗法的采用率增加。

内容

第一章研究方法论

  • 信息采购
  • 信息或数据分析
  • 市场製定和验证

第 2 章执行摘要

  • 竞争环境
  • 市场概况
  • 细分市场展望

第 3 章市场变量、趋势和范围

  • 2020 年治疗类型渗透和增长前景图
  • T 细胞疗法 - 市场动态
    • 市场驱动因素分析
      • 增加对用于治疗疾病的过继性 T 细胞转移方法的投资
      • 市场参与者之间的竞争加剧
      • Kymriah 和 Yescarta 在不同国家/地区获得批准
      • 针对实体瘤的 CAR-T 细胞疗法的开发
      • 製造过程中的技术进步
    • 市场製约因素分析
      • 与基因治疗相关的监管、科学和伦理问题
      • 昂贵的医疗费用
      • CAR T 限制
    • 机会分析
      • 扩大细胞和基因治疗设施
      • 增加对基因和细胞疗法的全球资助
      • 在病毒和非病毒载体製造领域的持续发展
  • 监管状况
    • 当前和未来可能获得的批准
    • 降低风险和安全监控框架
    • 当地监管框架
      • 美国
      • 欧洲
      • 中国
      • 日本
  • 过继细胞疗法 (ACT) 定价和支付模式
    • 保险范围
    • 基于价值的价格基准
    • 替代支付策略
  • 专利情况
  • 交易、筹款、伙伴关係和协作
    • 许可协议
    • 併购交易
    • 合作与伙伴关係
  • 管道分析
    • 临床试验情况
  • 公司地理分布图
  • CD19 定向 CART 疗法和其他 T 细胞疗法的竞争格局
  • T 细胞疗法市场 - SWOT 因素分析（政治和法律、经济、技术）
    • 政治形势
    • 经济状况
    • 社交情况
    • 技术概况
  • 行业分析 - 搬运工
    • 供应商的议价能力
    • 买家的议价能力
    • 替代威胁
    • 来自新进入者的威胁
    • 竞争公司之间的敌对关係

第 4 章 T 细胞治疗市场：模式估计和趋势分析

  • T 细胞疗法市场：模式变化分析
  • 研究
  • 产品

第 5 章 T 细胞疗法市场分类：治疗类型估计和趋势分析

  • T 细胞疗法市场：治疗类型的变化分析
  • CAR T 细胞疗法
  • 基于 T 细胞受体 (TCR)
  • 基于肿瘤浸润淋巴细胞 (TIL)

第 6 章 T 细胞疗法市场分类：适应症估计和趋势分析

  • T 细胞疗法市场：适应症波动分析
  • 血液系统恶性肿瘤
    • 淋巴瘤
    • 白血病
    • 骨髓瘤
  • 实体瘤
    • 黑色素瘤
    • 大脑和中枢神经系统
    • 肝癌
    • 其他
  • 其他

第 7 章 T 细胞疗法市场分类：按方式、治疗类型和适应症进行区域估计和趋势分析

  • 北美
    • SWOT 分析
    • 美国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 加拿大
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 欧洲
    • SWOT 分析
    • 德国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 英国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 法国
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 意大利
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 西班牙
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
      • 2018-2030 年西班牙 T 细胞疗法市场估计和预测（百万美元）
    • 丹麦
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 瑞典
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 挪威
      • 主要国家动态
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 亚太地区
    • SWOT 分析
      • 主要区域动态
    • 日本
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 中国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 印度
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 韩国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 澳大利亚
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 泰国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 拉丁美洲
    • SWOT 分析
    • 主要地区动态
    • 巴西
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 墨西哥
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿根廷
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
  • 中东和非洲 (MEA)
    • SWOT 分析
    • 主要地区动态
    • 南非
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 沙特阿拉伯
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 阿拉伯联合酋长国
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景
    • 科威特
      • 目标疾病的患病率
      • 竞争场景
      • 监管框架
      • 赎回场景

第八章竞争格局

  • 战略框架
  • 公司简介
    • 诺华公司
      • 公司简介
      • 爱贝克思公司
      • 财务业绩
      • 产品基准
      • 战略举措
    • 吉利德科学
      • 公司简介
      • 风筝製药
      • 财务业绩
      • 产品基准
      • 战略举措
    • 蓝鸟生物公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • TCR2 Therapeutics Inc.
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 索伦托疗法
      • 公司简介
      • 产品基准
      • 战略举措
    • 命运疗法
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 默克公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 辉瑞公司
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 安进
      • 公司简介
      • 财务业绩
      • 产品基准
      • 战略举措
    • 新基公司
      • 公司简介
      • 朱诺疗法
      • 财务业绩
      • 产品基准
      • 战略举措
Product Code: GVR-3-68038-685-1

T-cell Therapy Market Growth & Trends:

The global T-cell therapy market size is expected to reach USD 30.83 billion by 2030 and is expected to register a CAGR of 17.6% from 2023 to 2030 according to a new report by Grand View Research, Inc. The landmark approval of Kymriah and Yescarta have boosted advancements in the market. The launch of such therapies has strenghtned cash flow for innovation in this area resulting in market growth.

The shifting patients' preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.

Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.

An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.

The development of CAR T treatments for non-hematological malignancies has been significantly hampered by the antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilising a data-driven approach to research this area.

T-cell Theraphy Market Report Highlights:

  • By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.
  • Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.
  • By therapy type, CAR-T cell therapy dominated the segment in 2022 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.
  • Haematological malignancies dominated the indication segment in 2022. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.
  • North America dominated the overall global market. The regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.

Table of contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Competition Milieu
  • 2.2 Market Snapshot
  • 2.3 Segment Outlook

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
  • 3.2 T-Cell Therapy - Market Dynamics
    • 3.2.1 Market driver analysis
      • 3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
      • 3.2.1.2 Growing competition among market players
      • 3.2.1.3 Approval of Kymriah and Yescarta across various countries
      • 3.2.1.4 Developments in CAR T-cell therapy for solid tumors
      • 3.2.1.5 Technological advancements in manufacturing process
    • 3.2.2 Market restraint analysis
      • 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
      • 3.2.2.1 High prices of therapies
      • 3.2.2.2 CAR T limitations
    • 3.2.3 Opportunity analysis
      • 3.2.3.1 Facility expansion for cell and gene therapies
      • 3.2.3.1 Rising global financings in gene and cell therapy arena
      • 3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
  • 3.3 Regulatory Landscape
    • 3.3.1 Current and potential future approvals
    • 3.3.2 Frameworks for risk mitigation and safety monitoring
    • 3.3.3 Regulatory framework, by geography
      • 3.3.3.1 U.S.
      • 3.3.3.2 Europe
      • 3.3.3.3 China
      • 3.3.3.4 Japan
  • 3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
    • 3.4.1 Insurance coverage
    • 3.4.2 Value-based price benchmarks
    • 3.4.3 Alternate payment strategies
  • 3.5 Patent Landscape
  • 3.6 Deals, Funding's, Partnerships and Collaborations
    • 3.6.1 Licensing deals
    • 3.6.2 Merger & acquisition deals
    • 3.6.3 Collaboration & partnerships
  • 3.7 Pipeline Analysis
    • 3.7.1 Clinical trial landscape
  • 3.8 Geographic Mapping of Companies
  • 3.9 Competitive Landscape for CD19­directed CAR­T Therapies and Other T-cell therapies
  • 3.10 T-cell Therapy Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
    • 3.10.1 Political landscape
    • 3.10.2 Economic landscape
    • 3.10.3 Social landscape
    • 3.10.4 Technology landscape
  • 3.11 Industry Analysis - Porter's
    • 3.11.1 Supplier bargaining power
    • 3.11.2 Buyer bargaining power
    • 3.11.3 Substitution threat
    • 3.11.4 Threat from new entrant
    • 3.11.5 Competitive rivalry

Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis

  • 4.1 T-cell Therapy Market: Modality Movement Analysis
  • 4.2 Research
    • 4.2.1 Global research-based T-cell therapy market, 2018 - 2030 (USD Million)
  • 4.3 Commercialized
    • 4.3.1 Global commercial T-cell therapy market, 2018 - 2030 (USD Million)

Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis

  • 5.1 T-cell Therapy Market: Therapy Type Movement Analysis
  • 5.2 CAR T-cell Therapy
    • 5.2.1 Global CAR T-cell Therapy market, 2018 - 2030 (USD Million)
  • 5.3 T Cell Receptor (TCR)-based
    • 5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2018 - 2030 (USD Million)
  • 5.4 Tumor Infiltrating Lymphocytes (TIL)-based
    • 5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2018 - 2030 (USD Million)

Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis

  • 6.1 T-cell Therapy Market: Indication Movement Analysis
  • 6.2 Hematologic Malignancies
    • 6.2.1 Global T-cell therapy market for hematologic malignancies, 2018 - 2030 (USD Million)
    • 6.2.2 Lymphoma
      • 6.2.2.1 Global T-cell therapy market for lymphoma, 2018 - 2030 (USD Million)
    • 6.2.3 Leukemia
      • 6.2.3.1 Global T-cell therapy market for leukemia, 2018 - 2030 (USD Million)
    • 6.2.4 Myeloma
      • 6.2.4.1 Global T-cell therapy market for myeloma, 2018 - 2030 (USD Million)
  • 6.3 Solid Tumors
    • 6.3.1 Global T-cell therapy market for solid tumors, 2018 - 2030 (USD Million)
    • 6.3.2 Melanoma
      • 6.3.2.1 Global T-cell therapy market for melanoma, 2018 - 2030 (USD Million)
    • 6.3.3 Brain & Central Nervous System
      • 6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2018 - 2030 (USD Million)
    • 6.3.4 Liver cancer
      • 6.3.4.1 Global T-cell therapy market for liver cancer, 2018 - 2030 (USD Million)
    • 6.3.5 Others
      • 6.3.5.1 Global T-cell therapy market for other cancer forms, 2018 - 2030 (USD Million)
  • 6.4 Others
    • 6.4.1 Global T-cell therapy market for others, 2018 - 2030 (USD Million)

Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality, Therapy Type & Indication

  • 7.1 North America
    • 7.1.1 SWOT Analysis
      • 7.1.1.1 North America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key country dynamics
      • 7.1.2.2 Target disease prevalence
      • 7.1.2.3 Competitive scenario
      • 7.1.2.4 Regulatory framework
      • 7.1.2.5 Reimbursement scenario
      • 7.1.2.6 U.S. T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key country dynamics
      • 7.1.3.2 Target disease prevalence
      • 7.1.3.3 Competitive scenario
      • 7.1.3.4 Regulatory framework
      • 7.1.3.5 Reimbursement scenario
      • 7.1.3.6 Canada T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis
      • 7.2.1.1 Europe T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 Germany
      • 7.2.2.1 Key country dynamics
      • 7.2.2.2 Target disease prevalence
      • 7.2.2.3 Competitive scenario
      • 7.2.2.4 Regulatory framework
      • 7.2.2.5 Reimbursement scenario
      • 7.2.2.6 Germany T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 UK
      • 7.2.3.1 Key country dynamics
      • 7.2.3.2 Target disease prevalence
      • 7.2.3.3 Competitive scenario
      • 7.2.3.4 Regulatory framework
      • 7.2.3.5 Reimbursement scenario
      • 7.2.3.6 UK T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key country dynamics
      • 7.2.4.2 Target disease prevalence
      • 7.2.4.3 Competitive scenario
      • 7.2.4.4 Regulatory framework
      • 7.2.4.5 Reimbursement scenario
      • 7.2.4.6 France T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key country dynamics
      • 7.2.5.2 Target disease prevalence
      • 7.2.5.3 Competitive scenario
      • 7.2.5.4 Regulatory framework
      • 7.2.5.5 Reimbursement scenario
      • 7.2.5.6 Italy T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key country dynamics
      • 7.2.6.2 Target disease prevalence
      • 7.2.6.3 Competitive scenario
      • 7.2.6.4 Regulatory framework
      • 7.2.6.5 Reimbursement scenario
      • 7.2.6.6 Spain T-cell therapy market estimates and f.orecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key country dynamics
      • 7.2.7.2 Target disease prevalence
      • 7.2.7.3 Competitive scenario
      • 7.2.7.4 Regulatory framework
      • 7.2.7.5 Reimbursement scenario
      • 7.2.7.6 Denmark T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key country dynamics
      • 7.2.8.2 Target disease prevalence
      • 7.2.8.3 Competitive scenario
      • 7.2.8.4 Regulatory framework
      • 7.2.8.5 Reimbursement scenario
      • 7.2.8.6 Sweden T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key country dynamics
      • 7.2.9.2 Target disease prevalence
      • 7.2.9.3 Competitive scenario
      • 7.2.9.4 Regulatory framework
      • 7.2.9.5 Reimbursement scenario
      • 7.2.9.6 Norway T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.2.10 Rest Of Europe T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT analysis
      • 7.3.1.1 Key Region Dynamics
      • 7.3.1.2 Asia Pacific T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Target disease prevalence
      • 7.3.2.2 Competitive scenario
      • 7.3.2.3 Regulatory framework
      • 7.3.2.4 Reimbursement scenario
      • 7.3.2.5 Japan T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Target disease prevalence
      • 7.3.3.2 Competitive scenario
      • 7.3.3.3 Regulatory framework
      • 7.3.3.4 Reimbursement scenario
      • 7.3.3.5 China T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Target disease prevalence
      • 7.3.4.2 Competitive scenario
      • 7.3.4.3 Regulatory framework
      • 7.3.4.4 Reimbursement scenario
      • 7.3.4.5 India T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 South Korea
      • 7.3.5.1 Target disease prevalence
      • 7.3.5.2 Competitive scenario
      • 7.3.5.3 Regulatory framework
      • 7.3.5.4 Reimbursement scenario
      • 7.3.5.5 South Korea T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 Australia
      • 7.3.6.1 Target disease prevalence
      • 7.3.6.2 Competitive scenario
      • 7.3.6.3 Regulatory framework
      • 7.3.6.4 Reimbursement scenario
      • 7.3.6.5 Austrlia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 Thailand
      • 7.3.7.1 Target disease prevalence
      • 7.3.7.2 Competitive scenario
      • 7.3.7.3 Regulatory framework
      • 7.3.7.4 Reimbursement scenario
      • 7.3.7.5 Thailand T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.8 Rest Of Asia Pacific T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Latin America
    • 7.4.1 SWOT Analysis
    • 7.4.2 Key Regional Dynamics
      • 7.4.2.1 Latin America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Brazil
      • 7.4.3.1 Target disease prevalence
      • 7.4.3.2 Competitive scenario
      • 7.4.3.3 Regulatory framework
      • 7.4.3.4 Reimbursement scenario
      • 7.4.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Mexico
      • 7.4.4.1 Target disease prevalence
      • 7.4.4.2 Competitive scenario
      • 7.4.4.3 Regulatory framework
      • 7.4.4.4 Reimbursement scenario
      • 7.4.4.5 Mexico T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.5 Argentina
      • 7.4.5.1 Target disease prevalence
      • 7.4.5.2 Competitive scenario
      • 7.4.5.3 Regulatory framework
      • 7.4.5.4 Reimbursement scenario
      • 7.4.5.5 Argentina T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.6 Rest Of Latam T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis
    • 7.5.2 KEY regional Dynamics
      • 7.5.2.1 Middle East & Africa T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 South Africa
      • 7.5.3.1 Target disease prevalence
      • 7.5.3.2 Competitive scenario
      • 7.5.3.3 Regulatory framework
      • 7.5.3.4 Reimbursement scenario
      • 7.5.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 Saudi Arabia
      • 7.5.4.1 Target disease prevalence
      • 7.5.4.2 Competitive scenario
      • 7.5.4.3 Regulatory framework
      • 7.5.4.4 Reimbursement scenario
      • 7.5.4.5 Saudi Arabia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 UAE
      • 7.5.5.1 Target disease prevalence
      • 7.5.5.2 Competitive scenario
      • 7.5.5.3 Regulatory framework
      • 7.5.5.4 Reimbursement scenario
      • 7.5.5.5 UAE T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6 Kuwait
      • 7.5.6.1 Target disease prevalence
      • 7.5.6.2 Competitive scenario
      • 7.5.6.3 Regulatory framework
      • 7.5.6.4 Reimbursement scenario
      • 7.5.6.5 Kuwait T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.7 Rest of MEA T-cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Company Profiles
    • 8.2.1 Novartis AG
      • 8.2.1.1 Company overview
      • 8.2.1.1.1 AveXis, Inc.
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Strategic initiatives
    • 8.2.2 Gilead Sciences
      • 8.2.2.1 Company overview
      • 8.2.1.1.1 Kite Pharma
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Strategic initiatives
    • 8.2.3 bluebird bio, Inc.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 TCR2 Therapeutics Inc
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Strategic initiatives
    • 8.2.5 Sorrento Therapeutics
      • 8.2.5.1 Company overview
      • 8.2.5.2 Product benchmarking
      • 8.2.5.3 Strategic initiatives
    • 8.2.6 Fate Therapeutics
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.3 Strategic initiatives
    • 8.2.7 Merck KGaA
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.3 Strategic initiatives
    • 8.2.8 Pfizer Inc.
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Strategic initiatives
    • 8.2.9 Amgen
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Strategic initiatives
    • 8.2.10 Celgene Corporation
      • 8.2.10.1 Company overview
      • 8.2.10.1.1 Juno Therapeutics
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 4 Global T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 5 Global T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 6 Global T-Cell Therapy Market by Region, 2018 - 2030 (USD Million)
  • Table 7 North America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 8 North America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 9 North America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 10 North America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 12 U.S. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 15 Canada T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 16 Canada T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 17 Europe T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 19 Europe T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Europe T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 21 Germany T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 22 Germany T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 Germany T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 24 U.K. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 25 U.K. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 26 U.K. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 27 France T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 28 France T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 France T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 30 Italy T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 31 Italy T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 32 Italy T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 33 Spain T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 34 Spain T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 35 Spain T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 36 Denmark T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 37 Denmark T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 39 Sweden T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 40 Sweden T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 42 Norway T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 43 Norway T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 44 Norway T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 49 China T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 50 China T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 51 China T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 52 Japan T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 53 Japan T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 54 Japan T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 55 India T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 56 India T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 57 India T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 58 South Korea T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 59 South Korea T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 61 Australia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 62 Australia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 63 Australia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 64 Thailand T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 65 Thailand T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 67 Latin America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 69 Latin America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 71 Brazil T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 72 Brazil T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 74 Mexico T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 75 Mexico T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 77 Argentina T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 78 Argentina T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 84 South Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 85 South Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 86 South Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 90 UAE T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 91 UAE T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 92 UAE T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
  • Table 93 Kuwait T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
  • Table 94 Kuwait T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 T-Cell Therapy, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 10 Penetration & Growth Prospect Mapping
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
  • Fig. 14 Regional Marketplace: Key Takeaways
  • Fig. 15 Global T-Cell Therapy Market for Commercialized,2018 - 2030 (USD Million)
  • Fig. 16 Global T-Cell Therapy Market for Research, 2018 - 2030 (USD Million)
  • Fig. 17 Global T-Cell Therapy Market for In-Situ Hybridization Diagnostics, 2018 - 2030 (USD Million)
  • Fig. 18 Global T-Cell Therapy Market for CAR T Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 19 Global T-Cell Therapy Market for T Cell Receptor (TCR)-based,2018 - 2030 (USD Million)
  • Fig. 20 Global T-Cell Therapy Market for Tumor Infiltrating Lymphocytes (TIL)-based, 2018 - 2030 (USD Million)
  • Fig. 21 Global T-Cell Therapy Market for Hematologic Malignancies,2018 - 2030 (USD Million)
  • Fig. 22 Global T-Cell Therapy Market for Lymphoma, 2018 - 2030 (USD Million)
  • Fig. 23 Global T-Cell Therapy Market for Leukemia, 2018 - 2030 (USD Million)
  • Fig. 24 Global T-Cell Therapy Market for Myeloma, 2018 - 2030 (USD Million)
  • Fig. 25 Global T-Cell Therapy Market for Solid Tumors, 2018 - 2030 (USD Million)
  • Fig. 26 Global T-Cell Therapy Market for Melanoma, 2018 - 2030 (USD Million)
  • Fig. 27 Global T-Cell Therapy Market for Brain and central nervous system, 2018 - 2030 (USD Million)
  • Fig. 28 Global T-Cell Therapy Market for Liver cancer,2018 - 2030 (USD Million)
  • Fig. 29 Global T-Cell Therapy Market for Others,2018 - 2030 (USD Million)
  • Fig. 30 Global T-Cell Therapy Market for Other Indications, 2018 - 2030 (USD Million)
  • Fig. 31 Regional Outlook, 2021 & 2030
  • Fig. 32 North America T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 33 U.S. T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 34 Canada T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 35 Europe T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 36 Germany T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 37 U.K. T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 38 France T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 39 Italy T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 40 Spain T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 41 Denmark T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 42 Sweden T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 43 Norway T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 45 Japan T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 46 China T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 47 India T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 48 Australia T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 49 South Korea T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 50 Thailand T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 51 Latin America T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 52 Brazil T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 53 Mexico T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 54 Argentina T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 56 South Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 58 UAE T-Cell Therapy Market 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait T-Cell Therapy Market 2018 - 2030 (USD Million)